ERS Genomics and Dyadic BioSolutions Forge Key CRISPR/Cas9 Licensing Agreement to Propel Biotech Innovations
ERS Genomics and Dyadic BioSolutions Sign Licensing Agreement
In a significant advancement for the biotechnology sector, ERS Genomics Limited and Dyadic Applied BioSolutions have entered into a non-exclusive licensing agreement, allowing Dyadic access to ERS' foundational CRISPR/Cas9 patent portfolio. Announced on November 10, 2025, this partnership is poised to enhance Dyadic's genetic engineering capabilities, facilitating innovative developments across various commercial applications.
The CRISPR/Cas9 technology, a revolutionary tool in genetic modification, has spurred a new wave of research and applications in life sciences. This agreement is expected to streamline Dyadic's processes in strain engineering and pathway optimization, ultimately leading to improvements in productivity and product quality. As the CEO of ERS Genomics, John E. Milad remarked,
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.